Glucagon‐like peptide‐1 receptor agonists in schizophrenia spectrum disorders: A systematic review and meta‐analysis of efficacy, safety and mental health outcomes
British Journal of Clinical Pharmacology · 09.11.2026
DOI: 10.1002/bcp.70892 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 09.11.2026. Verfasst von Débora Regina de Aguiar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Post Graduation Program in Evidence-Based Health, Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Aims
The purpose of this study is to evaluate efficacy, safety and mental‐health outcomes of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in adults with overweight or obesity and antipsychotic‐treated schizophrenia‐spectrum disorders.
Methods
PubMed/MEDLINE, Embase, PsycINFO, CENTRAL, Virtual Health Library (VHL) (Biblioteca Virtual em Saúde, BVS), Scopus, Web of Science and trial registries were searched on 28 August 2026. Random‐effects models pooled mean difference (MD) or standardized mean difference (SMD) with 95% Wald intervals; Hartung–Knapp–Sidik–Jonkman (HKSJ) intervals were computed in parallel. Missing change‐score SDs were imputed at r = 0.50 (sensitivity r = 0.25 and 0.75). Binary safety outcomes used Mantel–Haenszel risk ratios with a 0.5 continuity correction for zero cells.
Results
Six trials ( n = 446) were pooled; three ( n = 102) informed the primary outcome. The primary outcome of total symptom severity was imprecise (SMD − 0.21, 95% CI −0.60 to 0.19; HKSJ −1.02 to 0.61). Functioning, Alcohol Use Disorders Identification Test (AUDIT), Schizophrenia Quality of Life Scale (SQLS) and Brief Assessment of Cognition in Schizophrenia (BACS) were likewise imprecise; all intervals included the null. Secondary mental‐health analyses were exploratory and unadjusted for multiplicity. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) reduced body weight (MD − 7.42 kg, −11.52 to −3.33; I 2 = 94%), body mass index (BMI, −2.77 kg m −2 ), waist circumference (−5.53 cm) and HbA1c (−0.36%). Gastrointestinal events were more frequent; serious adverse events were not. Weight heterogeneity tracked agent, dose, duration and antipsychotic background.
Conclusions
GLP‐1 RAs were associated with improvements in cardiometabolic measures over 12–36 weeks, although certainty for body weight was limited by heterogeneity and risk of bias. Mental‐health estimates were imprecise and did not allow a clear conclusion regarding benefit or harm. Cardiovascular events were not assessed, and no conclusions can be drawn regarding cardiovascular outcomes in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Post Graduation Program in Evidence-Based Health, Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil.
- Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina.
- Department of Medicine, Federal University of Catalão, Catalão, Brazil.
- Department of Health, State University of Feira de Santana, Feira de Santana, Brazil.
- Department of Medicine, Ingá University Center, Maringá, Brazil.
- Faculty of Nursing, State University of Goiás, Itumbiara Campus, Itumbiara, Brazil.
ORCID-Profile: Débora Regina de Aguiar, Samuel Izaias Dos Santos Pereira, Pedro Batista Castro, Carlos Ricardo Oliveira Carneiro, Julia Costa de Araujo, Rebeca Ferreira de Souza, Otavio André Farias Sousa da Silva, Matheus Hissa Lourenço Ferreira, Bruna Loureiro Fontana Bolsoni, Nelson Carvas Junior, Mario Rodrigues Louzã
Förderung
- Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
de Aguiar, D. R., Pereira, S. I. D. S., Castro, P. B., Carneiro, C. R. O., de Araujo, J. C., de Souza, R. F., da Silva, O. A. F. S., Ferreira, M. H. L., Bolsoni, B. L. F., Carvas Junior, N., & Louzã, M. R. (2026). Glucagon‐like peptide‐1 receptor agonists in schizophrenia spectrum disorders: A systematic review and meta‐analysis of efficacy, safety and mental health outcomes. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70892
Vancouver
de Aguiar DR, Pereira SIDS, Castro PB, Carneiro CRO, de Araujo JC, de Souza RF, et al. Glucagon‐like peptide‐1 receptor agonists in schizophrenia spectrum disorders: A systematic review and meta‐analysis of efficacy, safety and mental health outcomes. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70892
BibTeX
@article{deAguiar2026,
author = {de Aguiar, Débora Regina and Pereira, Samuel Izaias Dos Santos and Castro, Pedro Batista and Carneiro, Carlos Ricardo Oliveira and de Araujo, Julia Costa and de Souza, Rebeca Ferreira and da Silva, Otavio André Farias Sousa and Ferreira, Matheus Hissa Lourenço and Bolsoni, Bruna Loureiro Fontana and Carvas Junior, Nelson and Louzã, Mario Rodrigues},
title = {Glucagon‐like peptide‐1 receptor agonists in schizophrenia spectrum disorders: A systematic review and meta‐analysis of efficacy, safety and mental health outcomes},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70892}
}
EUVIMED